Abstrak & Penerbitan

Pemilihan Abstrak & Penerbitan Oleh Cytopeutics

Dengan kerjasama institusi perubatan tempatan dan antarabangsa, ahli akademik dan organisasi penyelidikan, Cytopeutics® telah menerbitkan banyak penemuan dalam peer-reviewed antarabangsa jurnal serta persidangan antarabangsa.

Heart Disease-01
Lihat Butiran
Heart Disease-02
Lihat Butiran
Heart Disease-03
Lihat Butiran
Lung Disease
Lihat Butiran
Chronic Kidney Disease
Lihat Butiran
Acute Stroke
Lihat Butiran
Brain & Spinal Cord
Lihat Butiran
Diabetes-01
Lihat Butiran
Diabetes-02
Lihat Butiran
CLV 100 Immunomodulation
Lihat Butiran
Autoimmune Disease
Lihat Butiran
GVHD
Lihat Butiran
EMIT
Lihat Butiran
Knee Osteoarthritis-01
Lihat Butiran
Knee Osteoarthritis-02
Lihat Butiran
Liver Disease
Lihat Butiran
Eye Disease-01
Lihat Butiran
Eye Disease-02
Lihat Butiran
Critical Limb Ischemia
Lihat Butiran

Pelajari Lebih Lanjut Tentang Cytopeutics

Mari Berbicara

Send Us a Message

Logo

Cytopeutics® is the multi-award winning and trusted provider of mesenchymal stem cells (MSC) for clinical trials and treatment in the Asia-Pacific region.

Instagram
Sitemap
About Us
Get In Touch
  • Phone
  • Mail
  • ENG / CN
  • ENG / BM
× Send

Copyright © Cytopeutics Sdn. Bhd. (Company No:200701018117 (776128-H)). Website managed by Exabytes. All rights reserved.

Synergistic effects of intracoronary infusion of autologous bone marrow-derived mesenchymal stem cells and revascularization procedure on improvement of cardiac function in patients with sever ischemic cardiomyopathy.
Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll/lll randomized controlled trial.
Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy.
Improved cells survival and paracrine capacity of human embryonic stem cell-derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension.
Mesenchymal stromal cells (Cyto-MSC) are well-tolerated and associated with renal function improvement in patients with chronic kidney disease: An observation retrospective study.
BM-MSC accelerates acute stroke recovery in a randomized placebo- controlled clinical phase ll/lll study.
Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro.
Allogenic cord-derived MSC infusion is safe and improves metabolic functions of uncontrolled diabetes patients.
Allogenic Wharton’s jelly mesenchymal stromal cells intravenous infusion increase serum insulin like growth factor 1 and dehydroepiandrosterone in healthy volunteers.
Dose-dependent immunomodulatory effect of intravenous allogenic umbilical cord-derived mesenchymal stromal cells (Cytopeutics CLV-100) infusion in healthy volunteers.
Autologous bone marrow mesenchymal stromal cells can treat arthritic joints of rheumatoid arthritis patients: Reports of two patients.
Cytopeutics® umbilical cord mesenchymal stromal cells (CYTO-MSC) for patients with grade ll-lv acute graft-versus-host disease: A phase l/ll clinical study-protocol overview.
A safe and simple approach to obtaining sufficient cytokine induced killer (CIK) cells from criticallyill cancer patients without the need for apheresis or peripheral mobilization.
Arthroscopic evidence of cartilage regeneration in severe knee cartilage defects and osteoarthritis following treatment with allogenic umbilical cord-derived mesenchymal stromal cells (Chondrocell- Ex).
Intra articular injection of autologous bone-marrow-derived mesenchymal stromal cells in patients with moderate to severe osteoarthritis.
Umbilical cord-derived mesenchymal stem cell infusion improved liver function in liver cirrhosis and is associated with viral load reduction.
Autologous cultivated oral mucosal epithelial cells transplantation (COMET) with amniotic membrane-based sheets for severe ocular chemical injury.
Safety and efficacy of human Wharton’s jelly-derived mesenchymal stem cells therapy for retinal degeneration.
Combination BM-MSC with BM-MNC is better than BM-MNC alone in resolution of large ischemic ulcers: A phase ll/lll clinical randomized study.